Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.

Learn more about whether Glaukos Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades ...

4. Zimmer Biomet has entered into a definitive agreement to purchase Paragon 28, a medical device company focused exclusively on foot-and-ankle orthopedics.

Inari is poised to enhance Stryker's footprint ... The company’s portfolio of mechanical thrombectomy devices is set to ‘complement’ Stryker’s neurovascular division.

On Tuesday, Canaccord Genuity adjusted its stance on Inari Medical (TASE:PMCN) Inc. (NASDAQ: NARI) stock, downgrading it from Buy to Hold, while increasing the price target to $80.00, up from the ...

Stryker's definitive agreement to purchase Inari Medical aims to enhance its product offerings by adding Inari's mechanical thrombectomy devices to its neurovascular portfolio. The integration is ...

Inari shareholders are getting a fair price ... stents, and mechanical thrombectomy devices. It’s a business that Stryker has built through a combination of internal R&D and M&A, including ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

The medical device maker plans to buy all of Inari's common stock for $80 a share, representing a total fully diluted equity value of about $4.9 billion. Inari makes mechanical thrombectomy ...

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ...